---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179828"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:26.657531+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3

## Summary
- Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.
- Cash and cash equivalents of $220.9M as of June 30, 2025; expected runway through 2027.
- JADE101 preclinical data presented; Phase 1 healthy-volunteer study to begin Q3 2025 with interim data H1 2026.
- Appointed Brad Dahms as CFO; previously CFO at IDRx, Theseus, Selecta.
- JADE201 development candidate from JADE-002 program on track for clinic in H1 2026; details expected H2 2025.

## SEC filing metadata
- accession: 0001193125-25-179828
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/0001193125-25-179828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/d82765d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179828
- JSON: https://secwatch.observer/filing/0001193125-25-179828.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.